Quest Partners LLC Sells 9,179 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Quest Partners LLC reduced its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 51.6% during the third quarter, HoldingsChannel reports. The firm owned 8,607 shares of the company’s stock after selling 9,179 shares during the period. Quest Partners LLC’s holdings in Fulgent Genetics were worth $187,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of FLGT. State Board of Administration of Florida Retirement System bought a new position in shares of Fulgent Genetics during the first quarter valued at $178,000. Vanguard Group Inc. lifted its holdings in Fulgent Genetics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,424,448 shares of the company’s stock valued at $30,911,000 after acquiring an additional 8,257 shares during the period. CANADA LIFE ASSURANCE Co lifted its holdings in Fulgent Genetics by 11.0% in the first quarter. CANADA LIFE ASSURANCE Co now owns 29,103 shares of the company’s stock valued at $631,000 after acquiring an additional 2,879 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Fulgent Genetics by 32.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,261 shares of the company’s stock valued at $310,000 after acquiring an additional 3,458 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in Fulgent Genetics by 36.4% in the second quarter. SG Americas Securities LLC now owns 12,826 shares of the company’s stock valued at $252,000 after acquiring an additional 3,425 shares during the period. 48.06% of the stock is owned by institutional investors.

Fulgent Genetics Stock Performance

FLGT stock opened at $18.07 on Thursday. The business’s 50-day moving average is $19.96 and its two-hundred day moving average is $21.16. The company has a market cap of $552.76 million, a price-to-earnings ratio of -3.27 and a beta of 1.51. Fulgent Genetics, Inc. has a fifty-two week low of $16.56 and a fifty-two week high of $30.68.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on FLGT shares. Piper Sandler lowered their target price on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, November 11th. StockNews.com downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday.

Insiders Place Their Bets

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,227 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.26, for a total value of $40,665.02. Following the completion of the sale, the chief executive officer now owns 703,711 shares in the company, valued at $12,849,762.86. This represents a 0.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 3,413 shares of company stock worth $62,321 over the last quarter. 32.66% of the stock is currently owned by corporate insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.